Literature DB >> 19564582

Incidence and prevalence of CIDP and the association of diabetes mellitus.

R S Laughlin1, P J Dyck, L J Melton, C Leibson, J Ransom, P J B Dyck.   

Abstract

BACKGROUND: The reported prevalence of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) varies greatly, from 1.9 to 7.7 per 100,000. CIDP is reported to occur more commonly in patients with diabetes mellitus (DM) but has not been rigorously tested.
OBJECTIVES: To determine the incidence (1982-2001) and prevalence (on January 1, 2000) of CIDP in Olmsted County, Minnesota, and whether DM is more frequent in CIDP.
METHODS: CIDP was diagnosed by clinical criteria followed by review of electrophysiology. Cases were coded as definite, probable, or possible. DM was ascertained by clinical diagnosis or current American Diabetes Association glycemia criteria.
RESULTS: One thousand five hundred eighty-one medical records were reviewed, and 23 patients (10 women and 13 men) were identified as having CIDP (19 definite and 4 probable). The median age was 58 years (range 4-83 years), with a median disease duration at diagnosis of 10 months (range 2-64 months). The incidence of CIDP was 1.6/100,000/year. The prevalence was 8.9/100,000 persons on January 1, 2000. Only 1 of the 23 CIDP patients (4%) also had DM, whereas 14 of 115 age- and sex-matched controls (12%) had DM.
CONCLUSIONS: 1) The incidence (1.6/100,000/year) and prevalence (8.9/100,000) of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) are similar to or higher than previous estimates. 2) The incidence of CIDP is similar to that of acute inflammatory demyelinating polyradiculoneuropathy within the same population. 3) Diabetes mellitus (DM) is unlikely to be a major risk covariate for CIDP, but we cannot exclude a small effect. 4) The perceived association of DM with CIDP may be due to misclassification of other forms of diabetic neuropathies and excessive emphasis on electrophysiologic criteria.

Entities:  

Mesh:

Year:  2009        PMID: 19564582      PMCID: PMC2707109          DOI: 10.1212/WNL.0b013e3181aaea47

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  30 in total

1.  Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Guillaume Nicolas; Thierry Maisonobe; Nadine Le Forestier; Jean-Marc Léger; Pierre Bouche
Journal:  Muscle Nerve       Date:  2002-01       Impact factor: 3.217

Review 2.  Research criteria for defining patients with CIDP.

Authors:  Howard W Sander; Norman Latov
Journal:  Neurology       Date:  2003-04-01       Impact factor: 9.910

3.  Distal acquired demyelinating symmetric neuropathy.

Authors:  J S Katz; D S Saperstein; G Gronseth; A A Amato; R J Barohn
Journal:  Neurology       Date:  2000-02-08       Impact factor: 9.910

4.  The spectrum of chronic inflammatory demyelinating polyneuropathy.

Authors:  F T Rotta; A T Sussman; W G Bradley; D Ram Ayyar; K R Sharma; R T Shebert
Journal:  J Neurol Sci       Date:  2000-02-15       Impact factor: 3.181

5.  Chronic inflammatory demyelinating polyradiculoneuropathy in diabetic patients.

Authors:  Rizwan U Haq; William W Pendlebury; Timothy J Fries; Rup Tandan
Journal:  Muscle Nerve       Date:  2003-04       Impact factor: 3.217

Review 6.  Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment.

Authors:  P James B Dyck; Anthony J Windebank
Journal:  Muscle Nerve       Date:  2002-04       Impact factor: 3.217

7.  Symptomatic diabetic and non-diabetic neuropathies in a series of 100 diabetic patients.

Authors:  Pierre Lozeron; Laurence Nahum; Catherine Lacroix; Angèle Ropert; Jean-Marc Guglielmi; Gérard Said
Journal:  J Neurol       Date:  2002-05       Impact factor: 4.849

8.  Demyelinating neuropathy in diabetes mellitus.

Authors:  Khema R Sharma; John Cross; Oscar Farronay; D Ram Ayyar; Robert T Shebert; Walter G Bradley
Journal:  Arch Neurol       Date:  2002-05

9.  Chronic polyneuropathies in Vest-Agder, Norway.

Authors:  A Mygland ; P Monstad
Journal:  Eur J Neurol       Date:  2001-03       Impact factor: 6.089

10.  Comparison of electrodiagnostic abnormalities and criteria in a cohort of patients with chronic inflammatory demyelinating polyneuropathy.

Authors:  Paul Magda; Norman Latov; Thomas H Brannagan; Louis H Weimer; Russell L Chin; Howard W Sander
Journal:  Arch Neurol       Date:  2003-12
View more
  55 in total

Review 1.  Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy.

Authors:  Björn Tackenberg; Falk Nimmerjahn; Jan D Lünemann
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

2.  Fibronectin connecting segment-1 peptide inhibits pathogenic leukocyte trafficking and inflammatory demyelination in experimental models of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Chaoling Dong; Kelsey M Greathouse; Rebecca L Beacham; Steven P Palladino; E Scott Helton; Eroboghene E Ubogu
Journal:  Exp Neurol       Date:  2017-02-16       Impact factor: 5.330

Review 3.  Diabetic neuropathy: mechanisms, emerging treatments, and subtypes.

Authors:  James W Albers; Rodica Pop-Busui
Journal:  Curr Neurol Neurosci Rep       Date:  2014-08       Impact factor: 5.081

4.  VIP-expressing dendritic cells protect against spontaneous autoimmune peripheral polyneuropathy.

Authors:  Mehmet E Yalvac; William David Arnold; Syed-Rehan A Hussain; Cilwyn Braganza; Kimberly M Shontz; Kelly Reed Clark; Christopher M Walker; Eroboghene E Ubogu; Jerry R Mendell; Zarife Sahenk
Journal:  Mol Ther       Date:  2014-04-25       Impact factor: 11.454

Review 5.  Advances in the diagnosis, pathogenesis and treatment of CIDP.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2011-08-16       Impact factor: 42.937

6.  Two years' long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatment.

Authors:  Gisa Ellrichmann; Ralf Gold; Ilya Ayzenberg; Min-Suk Yoon; Christiane Schneider-Gold
Journal:  Ther Adv Neurol Disord       Date:  2016-12-09       Impact factor: 6.570

Review 7.  Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.

Authors:  Peter J Dyck; Bruce V Taylor; Jenny L Davies; Michelle L Mauermann; William J Litchy; Christopher J Klein; P James B Dyck
Journal:  Muscle Nerve       Date:  2015-08-13       Impact factor: 3.217

8.  CIDP associated with Sjögren's syndrome.

Authors:  Tabea Seeliger; Stefan Gingele; Lena Bönig; Franz Felix Konen; Sonja Körner; Nils Prenzler; Thea Thiele; Diana Ernst; Torsten Witte; Martin Stangel; Thomas Skripuletz
Journal:  J Neurol       Date:  2021-02-21       Impact factor: 4.849

Review 9.  Not all neuropathy in diabetes is of diabetic etiology: differential diagnosis of diabetic neuropathy.

Authors:  Roy Freeman
Journal:  Curr Diab Rep       Date:  2009-12       Impact factor: 4.810

10.  Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins.

Authors:  Mohamed Mahdi-Rogers; Yusuf A Rajabally
Journal:  Biologics       Date:  2010-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.